Fukuoka M, Takada M, Tamai S, Negoro S, Matsui K, Ryu S, Sakai N, Sakaguchi K
Gan To Kagaku Ryoho. 1984 Aug;11(8):1543-9.
Pleural effusion is a common complication in patients with malignant neoplasm. A randomized controlled study of intrapleural instillation of Adriamycin (control group, 30 patients) and Adriamycin Nocardia rubra cell wall skeleton (N-CWS group, 26 patients) with tube thoracostomy was performed in 55 patients with malignant pleural effusion due to primary lung cancer. The response rates for control of pleural effusion were 73.4% in the N-CWS group and 46.1% in the N-CWS group. These results suggest that intrapleural instillation using a combination of anti-cancer agent and immunopotentiator is an effective treatment for malignant pleurisy. Cardiac tamponade secondary to cancer is a life-threatening complication requiring immediate treatment. Twenty-four patients with malignant pericardial effusion were treated by intrapericardial instillation of anti-cancer drugs, such as Carbazilquinone, Mitomycin-C or ACNU, with pericardial drainage. The range of survival time from the instillation of anti-cancer drug was 3-365 days (average days). In only 4 patients, reaccumulation of pericardial effusion was recognized. There were no serious complications with this procedure. It was considered that local instillation of anti-cancer agents with pericardial drainage was a useful therapeutic modality for malignant pericarditis.
胸腔积液是恶性肿瘤患者常见的并发症。对55例因原发性肺癌导致恶性胸腔积液的患者进行了一项随机对照研究,将其分为胸腔内注入阿霉素组(对照组,30例患者)和胸腔内注入阿霉素红色诺卡氏菌细胞壁骨架(N-CWS组,26例患者)并行胸腔闭式引流术。胸腔积液控制的有效率在N-CWS组为73.4%,在对照组为46.1%。这些结果表明,联合使用抗癌药物和免疫增强剂进行胸腔内注入是治疗恶性胸膜炎的一种有效方法。癌症继发的心包填塞是一种危及生命的并发症,需要立即治疗。24例恶性心包积液患者通过心包内注入抗癌药物(如卡巴醌、丝裂霉素-C或嘧啶亚硝脲)并进行心包引流进行治疗。从注入抗癌药物到死亡的生存时间为3 - 365天(平均天数)。仅4例患者出现心包积液再次积聚。该操作未出现严重并发症。认为心包引流联合局部注入抗癌药物是治疗恶性心包炎的一种有效治疗方式。